Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the release of its latest preprint titled “Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking.” This study highlights the potential of integrating Quantum-Si’s benchtop Platinum® instrument with an innovative protein barcoding workflow, offering a sensitive and accessible approach to multiplexed protein analysis.

Protein barcoding has emerged as a powerful tool for multiplexed protein selection, analysis, and tracking, enabling advanced insights into proteomics research. Traditional detection methods, such as mass spectrometry, often face challenges related to quantification, cost, and accessibility. Quantum-Si addresses these challenges with a groundbreaking workflow that enhances the precision and sensitivity of protein barcoding, expanding its utility across applications like protein engineering, targeted drug delivery, and nucleic acid therapy development.

Study Highlights:

  • Validation of Peptide Barcodes: Development and validation of eight peptide barcodes designed to minimize detection bias and maximize sensitivity.
  • Streamlined Workflow: Optimized expression constructs and process that reduced the sample input requirement and the hands-on time to less than one hour.
  • Dynamic Range: Demonstrated ten-fold dynamic range, enabling robust detection of low abundance proteins.

“Combining our Platinum® Pro instrument with the recently launched protein Barcoding Kit enables unmatched sensitivity and accessibility in proteomics research,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “This study serves as a foundation for implementing protein barcoding workflows and NGPS across a range of applications, driving advancements in protein characterization and targeted therapeutic strategies. It aligns with our mission to revolutionize protein sequencing and expand its applications to deliver significant breakthroughs in research and drug development.”

By leveraging Quantum-Si’s single-molecule NGPS technology, the study also underscores the advantages of protein barcode sequencing compared to DNA barcodes which are limited in their ability to directly detect successful translation. Next-Generation Protein Sequencing™ provides a direct quantitative readout of protein expression and localization, offering a more precise method for development of nucleic acid delivery vectors like lipid nano-particles and adeno associated viruses.

To read the preprint, visit: Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking | Quantum-Si

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact Jeff Keyes Chief Financial Officer ir@quantum-si.com Media Contact Katherine Atkinson SVP, Commercial Marketing media@quantum-si.com

Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Quantum Si Charts.
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Quantum Si Charts.